Peptide names and research questions
Several familiar questions turn on a change of molecule. Others ask for human results that the present studies cannot provide.
BPC-157 effects
In animal and cell experiments, BPC-157 has been associated with tissue protection, repair and angiogenesis. The VEGFR2 work involved a chick membrane, rat hindlimb and cultured human vascular endothelial cells. Human benefits remain uncertain; the 2025 review describes only three small pilots.
BPC-157: growth hormone?
BPC-157 is a synthetic fifteen-amino-acid peptide based on a gastric protein sequence. Its name expands to Body Protection Compound. The musculoskeletal review discusses its investigational repair literature; identifying it as growth hormone would substitute a different molecule.
BPC-157 onset
A reliable human efficacy timeline has yet to be established. In rats and beagle dogs, its elimination half-life was under thirty minutes. Clearance measures disappearance; a clinical outcome study would establish when a benefit begins.
Liver safety
The two-adult infusion pilot reported no measurable hepatic biomarker changes and no observed adverse events. That small observation leaves long-term liver safety unresolved. The review of the human evidence stresses the lack of rigorous large-scale trials.
GHK-Cu effects
Its human topical studies concern skin appearance. The skin-regeneration review reports collagen, elastin and other matrix effects in cell studies (in vitro). GHK-Cu includes bound copper; the skin-penetration experiment specifically quantified copper delivered through prepared skin.
GHK-Cu mechanism
It is the tripeptide glycine-histidine-lysine holding a copper(II) ion. The review of its skin biology describes matrix synthesis and copper-dependent activities in cell studies (in vitro). There is a further step from those observations to the broader database-derived gene-expression claims, which still need confirmation in living tissue.
GHK-Cu and skin ageing
Small topical studies summarised in the 2025 anti-wrinkle review report improvements in skin appearance. A cosmetic endpoint is a specific observation. Broader systemic-ageing claims extend beyond that evidence, and validated human pharmacokinetic data for injectable GHK-Cu are absent.
GHK and GHK-Cu
GHK names the bare tripeptide; GHK-Cu names its copper complex. Copper coordination matters to reported tissue-remodelling activity. The distinction is especially easy to lose beside the hair trial of GHK plus 5-aminolevulinic acid, which tested another preparation again.
TB-500 identity
It is the synthetic acetylated seven-amino-acid fragment Ac-LKKTETQ from thymosin β4. Much of the cited repair research concerns the full-length parent protein. The 2026 review of unapproved peptide therapies describes scarce rigorous human safety data and substantial regulatory concerns.
Meaning of TB-500
TB refers to thymosin beta. The numeric designation has no documented scientific meaning in this site's source list. Ac-LKKTETQ identifies the fragment more precisely. The sequence answers the identity question more precisely than the designation can.
TB-500 research uses
Research cited under the name often examines full-length thymosin β4: its actin-binding structure, neurological outcomes in rats after stroke or safety in healthy volunteers. Each result needs the full-length protein identified before it can inform a discussion of the fragment.
TB-500 recovery evidence
Completed controlled human trials of the fragment are absent. Community recovery accounts are anecdotal, with no clinical evidence establishing the benefit. The sports-medicine review describes favourable animal findings alongside scarce human safety data and potential for serious harm. TB-500 is prohibited in tested sport.